Aktiekurser för samtliga börslistor - Dagens Industri
Analytikernas rekommendationer, kurser, analyser, diagram
NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced financial results for the second quarter ended June 30, 2020. “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high … 2020-05-13 NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a development-stage company developing treatments for rare … Protara’s lead drug candidate, TARA-002, is an investigational cell based therapy based on the broad immunostimulant OK-432, which is approved in Japan and Taiwan for lymphangiomas, including lymphatic malformations (LMs), which are rare, typically congenital, malformations of … NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs 2020-05-11 Pipeline Overview. TARA-002. TARA-002, Protara’s lead product candidate, is an investigational cell based therapy based on the broad immunostimulant OK-432, PROTARA THERAPEUTICS, INC. Get Protara Therapeutics Inc (TARA:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases.
Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company. The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders.
Aktiekurser för samtliga börslistor - Dagens Industri
NEW YORK, July 28, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation for TARA-002 for the treatment of Lymphatic Malformations (LMs). 2021-04-07 · Protara Therapeutics Inc., formerly ArTara Therapeutics Inc., is a clinical-stage company.
Analytikernas rekommendationer, kurser, analyser, diagram
The Company is focused on developing treatments for rare and specialty diseases. Its development programs focus on the treatment of rare diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2020-07-24 · About Protara Therapeutics, Inc. Protara is committed to identifying and advancing transformative therapies for people with rare and specialty diseases who have limited treatment options. “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “We recently received Rare Pediatric Disease Designation for TARA-002, our lead product candidate, for the treatment of Lymphatic Malformations. NEW YORK, July 24, 2020 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical stage company developing treatments for rare and specialty diseases with significant unmet needs 2020-05-26 · Protara Therapeutics Receives Fast Track Designation from U.S. FDA for Intravenous Choline Chloride for the Treatment of Intestinal Failure Associated Liver Disease May 26, 2020 08:30 ET | Source Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.
21 timmar sedan · Protara Therapeutics, a clinical-stage company, engages in the identifying and advancing transformative therapies for people with rare and specialty diseases. The company’s lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. PROTARA THERAPEUTICS, INC. : Press releases relating to PROTARA THERAPEUTICS, INC. Investor relations | Nasdaq: TARA | Nasdaq
2020-05-14 · PROTARA THERAPEUTICS AKTIE und aktueller Aktienkurs. Nachrichten zur Aktie Protara Therapeutics Inc Registered Shs | A2P4JE | TARA | US74365U1079
PROTARA THERAPEUTICS, INC. : Financial news and information Stock PROTARA THERAPEUTICS, INC. | Nasdaq: TARA | Nasdaq
A high-level overview of Protara Therapeutics, Inc. (TARA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Hur ser en glodlampa ut inuti
2020-07-24 --ArTara Therapeutics, Inc., a clinical-stage company identifying and advancing transformative therapies for people with rare and specialty diseases, today announced that it has changed its name 21 hours ago 2020-10-05 Protara Therapeutics, Inc. Quote & Chart - Click for current quote - TARA About Protara Therapeutics, Inc. (adapted from Protara Therapeutics, Inc. prospectus): They are committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options.
Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Agneta ojehagen
manniskovarde
biltrafik på djurgården
man supporting woman
kan man välja kejsarsnitt i sverige
ibo international champion
Analytikernas rekommendationer, kurser, analyser, diagram
Protara Therapeutics, Inc. 345 Park Avenue South 3rd Floor New York, NY 10010 Phone: +1 646-844-0337 info@protaratx.com “We are committed to advancing our pipeline of potentially transformative therapies in several areas of high unmet need,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics.
Analytikernas rekommendationer, kurser, analyser, diagram
Its development programs focus on the treatment of ra re diseases in structural and connective tissues, as well as rare hepatology/gastrointestinal and metabolic disorders. 2020-08-03 Protara Therapeutics revenue from 2013 to 2020. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services.
Invest in Protara Therapeutics … 2021-04-10 Pipeline. Our approach has the potential to provide one-time cures for certain rare inherited diseases affecting people around the world. We are developing ex vivo autologous gene therapies for a range of serious disorders where the disease burden on children, families and caregivers is immense and current treatment options are limited or do not exist. Protara’s product pipeline contains Choline Chloride.